Adagene Inc. (ADAG)
NASDAQ: ADAG · Real-Time Price · USD
1.950
-0.010 (-0.51%)
At close: Jun 13, 2025, 4:00 PM
1.940
-0.010 (-0.51%)
After-hours: Jun 13, 2025, 4:00 PM EDT
Adagene Revenue
In the year 2024, Adagene had annual revenue of $103.20K, down -99.43%. Adagene had revenue of $103.20K in the half year ending December 31, 2024, a decrease of -98.08%.
Revenue (ttm)
$103.20K
Revenue Growth
-99.43%
P/S Ratio
890.12
Revenue / Employee
$748
Employees
138
Market Cap
91.86M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ADAG News
- 17 days ago - Adagene to Present at Jefferies Global Healthcare Conference 2025 - GlobeNewsWire
- 22 days ago - Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 6 weeks ago - Adagene Appoints John Maraganore, Ph.D. as Executive Advisor - GlobeNewsWire
- 7 weeks ago - Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 2 months ago - Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit - GlobeNewsWire
- 3 months ago - Adagene to Present at Leerink's Global Healthcare Conference 2025 - GlobeNewsWire
- 3 months ago - Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer - GlobeNewsWire